基于绝对PASI值≤1、2、3或5的生物制剂治疗银屑病网络荟萃分析
该研究应用统计转换方法,从50项已发表研究的相对PASI改善数据推导出绝对PASI值≤1、2、3或5的患者比例,并对11种生物制剂方案和安慰剂在12周时的疗效进行频率学派网络荟萃分析。结果显示,基于绝对与相对PASI数据的治疗排名一致,brodalumab 210 mg每2周和ixekizumab 80 mg每2周最有效,其次为guselkumab 100 mg每8周和risankizumab 150 mg每12周。
要点
- 统计转换法可从相对PASI改善数据推导绝对PASI值。
- 绝对与相对PASI网络荟萃分析的治疗排名一致。
- brodalumab和ixekizumab在诱导期显示最高疗效。
核心结论
- 基于统计转换推导的绝对PASI数据与相对PASI数据的网络荟萃分析结果排名一致。
- brodalumab 210 mg每2周和ixekizumab 80 mg每2周为最有效的治疗方案。
研究设计与样本
- 应用PASI统计转换方法处理50项已发表研究中11种生物制剂方案和安慰剂在12周时的相对PASI改善数据。
- 采用频率学派网络荟萃分析(Rücker法)比较相对与绝对PASI数据的疗效。
主要发现
- 在绝对PASI 0至8范围内,治疗排名与相对PASI评分(100至60)结果一致。
- 在绝对和相对PASI网络荟萃分析中,brodalumab 210 mg每2周和ixekizumab 80 mg每2周最有效,其次为guselkumab 100 mg每8周和risankizumab 150 mg每12周。
临床怎么用
- 该统计模型生成的数据可用于在缺乏所有治疗绝对PASI数据时,为治疗目标的科学讨论提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In practice, the goal of treatment for patients with psoriasis is to achieve almost clear or clear skin and maintain disease control, regardless of baseline disease severity. However, identifying absolute Psoriasis Area and Severity Index (PASI) values for new treatment goals is challenging, as most clinical trials report relative PASI 50, 75, 90 or 100 improvements but rarely absolute PASI values achieved. OBJECTIVE: Our objective was to illustrate a statistical conversion method that was developed to derive absolute PASI values from available clinical trial data on relative PASI improvements. The results of network meta-analyses (NMAs) based on these derived data were then compared with those of NMAs based on the corresponding relative PASI improvement data for selected biologics for moderate-to-severe psoriasis. METHODS: The PASI statistical conversion method was applied to relative PASI improvement data for 11 biologic treatment regimens and placebo at 12 weeks using data from 50 published studies. The respective proportions of patients reaching absolute PASI values ≤1, 2, 3 or 5 were then calculated. Frequentist NMAs (Rücker method) were subsequently used to compare efficacy results across relative and absolute PASI data. RESULTS: The ranking of included treatment regimens for patients achieving absolute PASI 0 to 8 was aligned with results for relative PASI scores (from 100 to 60) at end of induction therapy. Across the range of PASI scores considered, the most effective treatment regimens based on both absolute and relative PASI NMAs were brodalumab 210 mg every 2 weeks and ixekizumab 80 mg every 2 weeks, followed by guselkumab 100 mg every 8 weeks and risankizumab 150 mg every 12 weeks. CONCLUSION: Data generated using this mathematical model will be useful to inform ongoing scientific discussions on treatment goals in the absence of primary absolute PASI data for all available treatments for moderate-to-severe plaque psoriasis.
引用
- Mrowietz U, Warren RB, Leonardi CL, et al. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. J Eur Acad Dermatol Venereol. 2021. PMID: 33480102. doi:10.1111/jdv.17130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。